BioNTech SE

Youtube Subscribe

Open: 91.88 Close: 90.91 Change: -0.97

What an AI found about BioNTech SE Company Inc Stock after reading the whole Internet.

This document will help you to evaluate BioNTech SE without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, Pfizer, company, clinical, BNTX, cancer, …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE. Pfizer Canada ULC has authorized the companies Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine. The current share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish.

Today's News

Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE. Pfizer Canada ULC has authorized the companies Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine. The first patient has been treated in a Phase 2 clinical trial. The BioNTech SE ADR BNTX, -2.50% shed 2.50%. The S&P 500 Index SPX fell 1.26% to 4,224.16 and Dow Jones Industrial Average DJIA fell 0.86% to 33,127.28. Analysts are downgrading their BioNTech SE (NASDAQ:BNTX) Outlook. After the downgrade, the consensus from BioNTECHs 16 analysts is for revenues of €4.7b in 2023, which would reflect a substantial 49% decline in sales. The current BioNTech SE [ BNTX ] share price is $90.86. The current share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish. Shares of BioNTech SE sank 6.1% toward a 2 1/2-year low in premarket trading Monday. Germany-based biotechnology company disclosed that it... biontech treats first subject in phase ii cancer vaccine. BioNTech stock dips after warning write-off of up to €900M on covid vaccine. Pfizer reported similar charges on Friday after its partner Pfizer ( NYSE: PFE ) reported similar charge on Friday. Pfizer-BioNTech COVID-19 Vaccine doses adapted to the XBB.1.5 variant, which has been approved and is being marketed in key geographies. According to Pfizer, the write-offs do not address Pfizer’s COVID.5 Vaccine dose. Pfizer expects to release its financial report for the third quarter. Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) The investigation concerns whether BioNTch and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. HSBC downgraded BioNTech SE to Hold with a price target of $111.00. HSBC analyst Rajesh Kumar has an average return of 2.7% when recommending BioNTECH SE (BNTX) Pfizer and BioNTech began a Phase 2b/3 safety and efficacy trial on August 5, 2020. Comirnaty has been tested in over 80 clinical trials since the first quarter of 2020. Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ:BNTX) The investigation concerns whether the Company engaged in securities fraud or other unlawful business practices. Sanofi invested €80 million in BioNTech and extended the mRNA cancer research collaboration between the two companies. Sanofi previously paid US$60 million upfront for the rights to five discovery-stage immunotherapies. Pfizer would assume sole responsibility for further clinical development and commercialization of flu vaccines. BioNTech SE - ADR has fallen 14.23% over the past month, closing at $110.43 on September 19. Shares in Pfizer were down by 2.5% when the market closed on 13 October compared to the pre-announcement market opening. Biontech Se stock quotes can also be displayed as NASDAQ : BNTX. If you had invested in BionTech Se stock at $14.24 in Oct 10, 2019, your return over the last 4 years would have been 554.78%. Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech expands late-stage clinical oncology portfolio. Autogene cevumeran (BNT122, RO7198457) is part of BioNTechs and Genentechs worldwide strategic collaboration to develop, manufacture and commercialize novel mRNA-based cancer vaccines, which was initiated in 2016.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

Are looking for the most relevant information about BioNTech SE? Investor spend a lot of time searching for information to make investment decisions in BioNTech SE. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, Pfizer, company, clinical, BNTX, cancer, and the most common words in the summary are: biontech, stock, vaccine, market, news, se, covid19, . One of the sentences in the summary was: The current share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #stock #vaccine #market #news #se #covid19.

Read more →

Youtube Subscribe

---